a transcription factor that is a member of the leucine zipper family. Binds to the cAMP-responsive element (CRE). Forms a homodimer or heterodimer with c-Jun and stimulates CRE-dependent transcription. Also possesses histone acetyltransferase (HAT) activity that specifically acetylates histones H2B and H4 in vitro. Note: This description may include information from UniProtKB.
Protein type: EC 22.214.171.124; C2H2-type zinc finger protein; Transcription factor
Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; protein binding; histone acetyltransferase activity; protein heterodimerization activity; metal ion binding; cAMP response element binding protein binding; transcription coactivator activity; chromatin binding; protein kinase binding; transcription factor activity
Biological Process: fat cell differentiation; transcription from RNA polymerase II promoter; establishment and/or maintenance of chromatin architecture; MyD88-independent toll-like receptor signaling pathway; stress-activated MAPK cascade; toll-like receptor 3 signaling pathway; response to osmotic stress; positive regulation of transforming growth factor-beta2 production; toll-like receptor 10 signaling pathway; toll-like receptor 2 signaling pathway; MyD88-dependent toll-like receptor signaling pathway; toll-like receptor 5 signaling pathway; regulation of transcription from RNA polymerase II promoter; regulation of transcription, DNA-dependent; regulation of transcription factor activity; intra-S DNA damage checkpoint; toll-like receptor signaling pathway; innate immune response; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; toll-like receptor 9 signaling pathway; histone acetylation; toll-like receptor 4 signaling pathway; response to DNA damage stimulus
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.